Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Therapy Type
3.2. Snippet by Cell Source
3.3. Snippet by Therapeutic Application
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Advancements in Regenerative Medicine
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. High Treatment Costs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs
6. By Therapy Type
6.1. Introduction
6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
6.1.2. Market Attractiveness Index, By Therapy Type
6.2. Autologous Stem Cell Therapy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Allogeneic Stem Cell Therapy
7. By Cell Source
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Source
7.1.2. Market Attractiveness Index, By Cell Source
7.2. Adipose Tissue-Derived Mesenchymal Stem Cells*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Bone Marrow-Derived Mesenchymal Stem Cells
7.4. Cord Blood/Embryonic Stem Cells
7.5. Others
8. By Therapeutic Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
8.1.2. Market Attractiveness Index, By Therapeutic Application
8.2. Musculoskeletal Disorders*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Neurological Disorders
8.4. Autoimmune Diseases
8.5. Cardiovascular Diseases
8.6. Wounds & Surgeries
8.7. Inflammatory
8.8. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Source
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Source
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Source
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Source
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Source
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Mesoblast Ltd*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Product Sales
11.1.2.4. Product Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals etc.
11.1.5. SWOT Analysis
11.2. Lineage Cell Therapeutics, Inc.
11.3. BlueRock Therapeutics LP
11.4. Orchard Therapeutics plc.
11.5. Vericel Corporation.
11.6. CRISPR Therapeutics AG
11.7. Fate Therapeutics, Inc.
11.8. Novartis AG
11.9. Bristol Myers Squibb (Juno Therapeutics, Inc.)
11.10. Bluebird Bio, Inc.
11.11. MEDIPOST Co., Ltd.
11.12. ANTEROGEN.CO.,LTD.
11.13. CORESTEMCHEMON Inc.
11.14. PHARMICELL Co., Ltd
11.15. JCR Pharmaceuticals Co., Ltd.
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us